Found 1 document(s)
Page 1 of 1
-
Aim: We conducted a systematic review to compare adverse effects (AE) and the reporting of harm in randomised controlled trials (RCTs) and non-RCTs evaluating intravitreal ranibizumab and bevacizumab in age-related macul...